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1480Background: Anemia and red blood cell (RBC) transfusions are both associated with morbidity and mortality
after cardiac surgery. Patients with the lowest hematocrit (HCT) values during cardiopulmonary bypass (CPB)
are the most likely to receive a transfusion, which results in a double-negative exposure. We aimed to clarify the
effects of anemia, transfusion, and their combination to identify which imposes the greatest risk of end-organ
dysfunction and mortality.
Methods: From November 1, 2004, to November 1, 2009, 7942 patients underwent procedures requiring CPB
and did not receive intraoperative or postoperative RBC transfusion, and 1202 received intraoperative RBC
transfusion alone. They were divided into 4 groups: intraoperative nadir HCT 25% without RBC transfusion,
25% with RBC transfusion, <25% without RBC transfusion, and <25% with RBC transfusion. The
relationship among HCT, RBC, and outcomes was studied using generalized propensity-score analysis.
Outcomes included estimated glomerular filtration rate (eGFR), troponin, ventilatory support time, length of
stay, and mortality.
Results:After risk adjustment, comparison of all 4 groups showed that double exposure to anemia (HCT<25%)
and RBC transfusion was associated with the highest risk: lowest eGFR (P ¼ .008), highest troponin values
(P ¼ .01), longest ventilator requirement (P<.001), longest length of stay (P<.001), and highest mortality
(P ¼ .007). Single exposure to either HCT<25% or RBC transfusion alone was associated with the next
risk category, and the lowest morbidity risk was associated with neither exposure.
Conclusions: Although single exposure to anemia or RBC transfusion alone was associated with risk, it was
generally lower than that of anemia and RBC exposure in combination. (J Thorac Cardiovasc Surg
2013;146:1480-7)Supplemental material is available online.
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The Journal of Thoracic and Cardiovascular Surthreats of developing anemia and receiving red blood cell
(RBC) transfusions. Our prior work and other investigations
have recognized increased morbidity among cardiac
surgical patients who develop perioperative anemia1-3 and
receive RBC transfusions.1,4-7 Although both of these
negative exposures may be avoidable, when physicians
must decide whether to circumvent patient exposure to
anemia by preemptive treatment with RBC transfusion or
to simply tolerate anemia, the trade-off with morbidity
risk is unclear.
Our objectives were to evaluate morbidity and survival
associated with 3 operative management strategies in
patients undergoing cardiac surgery requiring use of
cardiopulmonary bypass (CPB): (1) tolerating anemia
without RBC transfusion, (2) avoiding anemia with RBC
transfusion, and (3) exposing patients to both anemia and
its treatment, RBC transfusion.METHODS
Study Population
From November 1, 2004, to November 1, 2009, 15,282 patients at
Cleveland Clinic (Cleveland, OH) underwent cardiac surgical procedures
requiring CPB. Patients with missing intraoperative hematocrit (HCT)
values or aged younger than 18 years were excluded. Among the remaining
15,115 patients, 7942 (53%) did not receive an intraoperative or post-
operative RBC transfusion. Another 7173 (47%) received intraoperativegery c December 2013
Abbreviations and Acronyms
CPB ¼ cardiopulmonary bypass
eGFR ¼ estimated glomerular filtration rate
HCT ¼ hematocrit
LOS ¼ length of stay
RBC ¼ red blood cell
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Mor postoperative transfusions, or both. Among the transfused patients, 1202
(17%) had only intraoperative RBC transfusions and were included in the
study group. We included only intraoperative RBC transfusions to avoid
potential confounding associated with RBC transfusion occurring after
the morbidity event.
Our final study cohort comprised 9144 patients: 7942 nontransfused
(87%) and 1202 transfused only intraoperatively (13%). For comparison,
the study cohort was divided into 4 groups (Figure E1):
1. No negative exposures: nadir HCT 25% without RBC transfusion
(n ¼ 6937; 76%).
2. Single negative exposure: nadir HCT 25% with RBC transfusion
(n ¼ 246; 2.7%).
3. Single negative exposure: nadir HCT<25% without RBC transfusion
(n ¼ 1005; 11%).
4. Double negative exposure: nadir HCT<25% with RBC transfusion
(n ¼ 956; 10%).
Baseline and perioperative variables were retrieved from the Cleveland
Clinic Cardiovascular Information Registry and the Cardiothoracic
Anesthesia Database, ongoing, prospective, concurrent registries of all
cardiac operations maintained concurrently with patient care. They have
been approved for use in research by the Institutional Review Board,
with patient consent waived.
End Points
End points were markers of end-organ dysfunction (perioperative
myocardial infarction, renal and hepatic failure, neurologic complications,
and duration of postoperative ventilatory support), hospital mortality, and
long-term survival. Serial values of specific markers of end-organ dys-
function included estimated glomerular filtration rate (eGFR) and troponin
release level. Intensive care unit and postoperative lengths of stay (LOS)
were used as surrogates for resource use, as was duration of postoperative
ventilatory support. Hospital morbidities were recorded prospectively,
according to definitions from the Society of Thoracic Surgeons National
Adult Cardiac Database (http://www.ctsnet.org/file/rptDataSpecifications
252_1_ ForVendorsPGS.pdf).
Vital status was determined using Cardiovascular Information Registry
follow-up data supplemented with Social Security Death Master File
information.8,9 Median follow-up was 3.7 years, with 25% of patients
followed up for more than 5 years and 10% for more than 6 years;
33,775 patient-years of data were available for analysis. Nadir HCT
was defined as the lowest intraoperative HCT value obtained from
intraoperative arterial blood samples.
Data Analysis
Categorical variables are summarized by frequency and percentage, and
continuous variables by mean  SD, or by 15th, 50th (median), and 85th
percentiles when values are skewed. Comparisons were made using the
c2 test for categorical data and the Wilcoxon rank-sum or Kruskal-Wallis
nonparametric test (for >2 categories) for continuous data. Multiple
imputation using the Markov chain Monte Carlo technique was used to
impute missing values. Fivefold multiple imputation was performed with
PROC MI (SAS version 9.1; SAS Institute, Inc, Cary, NC). The estimatedThe Journal of Thoracic and Carregression coefficients and their variance-covariance matrix for each of the
5 imputed complete data sets were then combined following Rubin’s
methodology10 (PROC MIANALYZE; SAS Institute, Inc).
Adjusted effects of the 4 groups on outcomes were analyzed using
propensity-score methods.11,12 By using polytomous logistic regression
(generalized logit link with group 1 as the reference) and variables listed
in Appendix E1, we identified variables associated with group member-
ship. Having established a parsimonious model, we added other variables
representing groups of patients who may be related to these 4 groups
(saturated model). Three propensity scores (probability of being in groups
2, 3, and 4) were then estimated. Similar to traditional 2-group propensity-
score strategies, we used the scores in 2 ways: (1) subclassification
approach, in which we stratified the study population into 64 strata based
on the 3 scores, then adjusted for these strata in the outcome analyses of
eGFR, troponin, ventilatory support time, and postoperative LOS; and
(2) propensity-score adjustment, in which we forced the 3 scores into the
multivariable model of short- and long-term survival.
We used multivariable linear regression (PROC REG; SAS Institute,
Inc) and variables listed in Appendix E1 to identify variables associated
with continuous outcomes (eGFR, postoperative LOS, troponin, and
ventilatory support time) and multivariable binary logistic regression
(PROC LOGISTIC; SAS Institute, Inc) for binary outcomes.
Short- and long-term survival were assessed nonparametrically using
the Kaplan-Meier estimator and parametrically using a multiphase hazard
model.13 The parametric model was used to resolve several phases of
instantaneous risk of the event (hazard function) and to estimate shaping
parameters. Multivariable analyses were performed in the hazard function
domain. The final model was adjusted further by forcing in the 3 propensity
scores.
Bootstrap aggregation (bagging) was used for variable selection.14
P ¼ .05 was set for retention of variables. This was a 4-step process. First,
a patient was randomly selected from the original data set to begin a new
data set. The original data set continued to be sampled until the new data
set was 100% the size of the original. Second, risk factors were identified
using automated forward stepwise selection. Third, results of the variable
selection were stored. These 3 steps were repeated 500 times. Finally,
the frequency of occurrence of variables related to group membership
was ascertained and indicated the reliability of each variable (aggregation
step). All variables with bootstrap reliability of 50% or greater were
retained in the final model.14
For the troponin release model, patients who underwent atrial
fibrillation procedures or septal myectomy were excluded from the study
cohort; and for the postoperative LOS model, patients who died in the
hospital were excluded. For the troponin release, ventilatory support, and
postoperative LOS models, logarithmic transformation was used as the
response variable. Any one of the following was used as a neurologic
complication: coma (lasting at least 24 hours), permanent stroke, transient
ischemic attack, or paraplegia.
All analyses were performed using SAS version 9.1 and R software.15
The statistical significance level was set at .05. All P values are 2 sided.RESULTS
Intraoperative Nadir HCT and RBC Transfusion
The median intraoperative nadir HCT was 29%. Total
intraoperative RBC units transfused ranged from 1 to 30,
with 75% of patients receiving either 1 or 2 units. As
expected, transfused patients had lower intraoperative
nadir HCT values than nontransfused patients (Figure 1).
Baseline and perioperative variables, according to exposure
group, are presented in Table 1. Compared with patients not
having the negative exposures of anemia and transfusion,
those exposed to both were more likely to be older, to bediovascular Surgery c Volume 146, Number 6 1481
FIGURE 1. Histogram showing relationship between intraoperative nadir
hematocrit (HCT) and intraoperative redbloodcell (RBC) transfusion status.
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Mfemale, and to have a lower body mass index, a lower
preoperative hematocrit, and a longer CPB duration. They
were also more likely to have an unstable presentation
(ie, a higher prevalence of emergency operations, pre-
operative intra-aortic balloon pump use, and reoperations)
(Table 1 and Table E1).
72-Hour Minimum eGFR and Exposure Groups
Unadjusted analysis showed differences in postoperative
72-hour minimum eGFR among the 4 groups, with more
negative exposures associated with decreased renal function
(Table 2 and Figure 2, A). Compared with patients not
having negative exposures to anemia or transfusion,
patients exposed to anemia (HCT<25%) alone had a lower
eGFR (71  27 vs 78  22 mL $ min1 $ 1.73 m2). The
next worst eGFR was noted in patients with a single expo-
sure to transfusion without anemia (68  29 mL $ min1 $
1.73 m2). The greatest risk for renal dysfunction was
observed in patients with a double exposure to anemia
(HCT<25%) and transfusion (60  26 mL $ min1 $
1.73 m2), demonstrating that treating anemia with RBC
transfusion worsened, rather than helped, renal function.
Risk-adjusted analysis of renal function shows that
patients exposed to anemia (HCT<25%) had greater renal
dysfunction than those who were not anemic (Table 3,
Figure 3, A, and Table E2). However, patients with anemia
(HCT <25%) who also received an intraoperative1482 The Journal of Thoracic and Cardiovascular Surtransfusion fared worse than those who were anemic but
not transfused.
24-Hour Mean Troponin Release and Exposure
Groups
Unadjusted analysis revealed that patients with both
anemia (HCT<25%) and intraoperative RBC transfusion
had greater troponin release than those with anemia
(HCT <25%) alone, suggesting increased myocardial
injury (Table 2 and Figure 2, B).
Risk-adjusted analysis showed that patients with
exposure to anemia (HCT<25%) alone did not have a
significant increase in troponin release unless they also
were transfused (Table 3, Figure 3, B, and Table E3).
Furthermore, patients without anemia (HCT 25%) who
received an intraoperative transfusion to avoid it did not
have a significantly greater increase in troponin release
than those with no negative exposures.
Ventilatory Support Duration and Exposure Groups
Unadjusted analysis showed that patients exposed to
intraoperative RBC transfusion with (HCT <25%) or
without anemia had the longest postoperative ventilatory
support duration (Table 2 and Figure 2, C). However, in
the risk-adjusted analysis, patients with any negative
exposure to anemia (HCT<25%) and RBC transfusion
had longer ventilation times than patients without negative
exposures (Table 3, Figure 3, C, and Table E4).
Postoperative Length of Stay and Exposure Groups
Unadjusted analysis showed that patients who received
intraoperative RBC transfusion with (HCT <25%) or
without anemia had the longest postoperative LOS, suggest-
ing increased resource use (Table 2 and Figure 2, D).
This association persisted in the risk-adjusted analysis
(Table 3, Figure 3, D, and Table E5).
Other Complications and Exposure Groups
Unadjusted analysis revealed that neurologic complica-
tions occurred in 2.3% of patients with exposure to
both anemia (HCT<25%) and intraoperative RBC trans-
fusion, compared with 1% for those without anemia
(HCT 25%) and no transfusion (P ¼ .004; Table 2).
However, there was no statistically significant difference
in occurrences among the exposure groups after risk-
adjusted analysis (P > .2). The prevalence of hepatic
dysfunction was similar among the groups (Table 2), and
this held after risk adjustment.
Short- and Long-Term Survival and Exposure
Groups
The hazard function for death after surgery demonstrated
an early decreasing and a late increasing hazard phase.
Unadjusted analysis showed differences between groupsgery c December 2013
TABLE 1. Patient and procedural variables stratified by intraoperative nadir HCT and intraoperative RBC transfusion
Variable
Intraoperative nadir HCT and intraoperative RBC transfusion groups
P
value
Nadir HCT 25
and RBC ¼ 0
(total N ¼ 6937)
Nadir HCT<25
and RBC ¼ 0
(total N ¼ 1005)
Nadir HCT 25
and RBC>0
(total N ¼ 246)
Nadir HCT<25
and RBC>0
(total N ¼ 956)
No.* Measurey No.* Measurey No.* Measurey No.* Measurey
Demographics
Age, y 6937 59  13 1005 63  14 246 64  14 956 69  13 <.001
Female sex 6937 1345 (19) 1005 658 (65) 246 80 (33) 956 643 (67) <.001
Race
White 6881 6343 (92) 998 864 (87) 244 226 (93) 940 814 (87) <.001
Other 6881 538 (7.8) 998 134 (13) 244 18 (7.4) 940 126 (13) <.001
Preoperative BMI, kg $ m2 6813 29  5.7 995 28  6.4 242 29  5.7 934 28  6.3 <.001
Cardiac comorbidity
NYHA functional class 5979 882 207 829 <.001
I 1854 (31) 206 (23) 53 (26) 161 (19)
II 2944 (49) 411 (47) 79 (38) 373 (45)
III 1093 (18) 242 (27) 65 (31) 248 (30)
IV 88 (1.5) 23 (2.6) 10 (4.8) 47 (5.7)
Emergency operation 6935 24 (0.35) 1005 2 (0.20) 246 8 (3.3) 956 28 (2.9) <.001
Prior myocardial infarction 6937 1371 (20) 1005 207 (21) 246 90 (37) 956 296 (31) <.001
Preoperative atrial fibrillation/
flutter
6720 654 (9.7) 981 92 (9.4) 240 40 (17) 925 96 (10) .005
Prior cardiac operation 6937 898 (13) 1005 142 (14) 246 115 (47) 956 328 (34) <.001
Heart failure 6937 1146 (17) 1005 255 (25) 246 82 (33) 956 358 (37) <.001
Preoperative IABP use 6937 19 (0.27) 1005 7 (0.70) 246 6 (2.4) 956 7 (0.73) <.001
Cardiogenic shock 6937 21 (0.30) 1005 5 (0.50) 246 4 (1.6) 956 7 (0.73) .003
Ejection fraction,% 6728 54  11 981 54  11 234 49  14 910 52  12 <.001
Coronary artery disease
(50% stenosis)
6811 2311 (34) 981 317 (32) 237 86 (36) 918 397 (43) <.001
Noncardiac comorbidity
History of endocarditis 6937 226 (3.3) 1005 55 (5.5) 246 17 (6.9) 956 81 (8.5) <.001
History of smoking 6933 3526 (51) 1002 470 (47) 246 152 (62) 955 512 (54) .001
History of peripheral arterial
disease
6937 1683 (24) 1005 292 (29) 246 114 (46) 956 439 (46) <.001
History of carotid disease 6937 1556 (22) 1005 258 (26) 246 102 (41) 956 397 (42) <.001
History of COPD 6937 659 (9.5) 1005 133 (13) 246 45 (18) 956 178 (19) <.001
History of hypertension 6937 4370 (63) 1005 660 (66) 246 182 (74) 956 748 (78) <.001
Diabetes 6888 1254 (18) 1002 229 (23) 243 61 (25) 945 314 (33) <.001
History of renal disease 6937 91 (1.3) 1005 37 (3.7) 246 18 (7.3) 956 68 (7.1) <.001
Prior stroke 6937 341 (4.9) 1005 80 (8.0) 246 33 (13) 956 135 (14) <.001
Preoperative eGFR (MDRD) 6931 81  20 1005 77  25 246 76  31 956 69  27 <.001
Bilirubin, mg $ dL1 6865 0.72  0.41 994 0.6  0.43 242 0.73  0.48 944 0.62  0.54 <.001
Preoperative hematocrit,% 6937 43  4.2 1005 36  3.9 246 39  6.2 956 33  4.6 <.001
Procedure
No. of ITA grafts (>0) 6937 2089 (30) 1005 270 (27) 246 56 (23) 956 291 (30) <.001
Isolated CABG 6937 1430 (21) 1005 169 (17) 246 33 (13) 956 159 (17) .001
Isolated valve 6937 2151 (31) 1005 330 (33) 246 46 (19) 956 216 (23) <.001
Valve þ CABG 6937 614 (8.9) 1005 115 (11) 246 27 (11) 956 165 (17) <.001
Other procedures 6937 2742 (40) 1005 391 (39) 246 140 (57) 956 416 (44) <.001
No. of components 6937 1.6  0.85 1005 1.7  0.95 246 1.8  0.96 956 2.0  0.99 <.001
Times
Myocardial ischemia, min 6937 70  28 1005 68  30 246 77  39 956 80  36 <.001
Cardiopulmonary bypass, min 6937 90  34 1005 88  37 246 115  45 956 112  45 <.001
1/1/2004 to index operation, y 6937 3.3  1.4 1005 3.4  1.6 246 2.9  1.3 956 3.4  1.5 <.001
HCT, Hematocrit; RBC, red blood cell; BMI, body mass index; NYHA, New York Heart Association; IABP, intra-aortic balloon pump; COPD, chronic obstructive
pulmonary disease; eGFR, estimated glomerular filtration rate;MDRD, modification of diet in renal disease; ITA, internal thoracic artery; CABG, coronary artery bypass grafting.
*Patients with data available. yNumber (percentage) or mean  SD.
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TABLE 2. Comparison of end-organ dysfunction and hospital complications stratified by intraoperative nadir HCT and intraoperative RBC
transfusion
Complication
Intraoperative nadir HCT and intraoperative RBC transfusion groups
P
value
Nadir HCT 25
and RBC ¼ 0
(total N ¼ 6937)
Nadir HCT<25
and RBC ¼ 0
(total N ¼ 1005)
Nadir HCT 25
and RBC>0
(total N ¼ 246)
Nadir HCT<25
and RBC>0
(total N ¼ 956)
No.* Measurey No.* Measurey No.* Measurey No.* Measurey
72-h Minimum eGFR (MDRD) 6934 78  22 1004 71  27 245 68  29 946 60  26 <.001
24-h Mean troponin 6530 0.23/0.52/1.5 912 0.21/0.53/1.6 228 0.28/0.67/1.9 905 0.31/0.74/1.8 <.001
Ventilatory support, h 6496 3.5/6.0/16 971 3.6/6.4/17 244 4.8/12/36 948 4.8/11/22 <.001
Neurologic complication 6937 72 (1.0) 1005 8 (0.80) 246 4 (1.6) 956 22 (2.3) .004
GI, MSOF, or bleeding/embolic 6937 93 (1.3) 1005 15 (1.5) 246 7 (2.8) 956 18 (1.9) .16
Length of stay
ICU, h 6937 22/26/52 1005 21/27/67 246 24/46/98 956 23/44/99 <.001
Postoperative, d 6937 4.2/6.0/9.0 1005 4.8/6.2/10 246 5.3/7.9/13 956 5.4/8.0/13 <.001
HCT, Hematocrit; RBC, red blood cell; eGFR, estimated glomerular filtration rate; MDRD, modification of diet in renal disease; GI, gastrointestinal; MSOF, multisystem organ
failure; ICU, intensive care unit. *Patients with data available. yNumber (percentage), mean  SD, or 15th/50th/85th percentiles.
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intraoperative RBC transfusion associated with the lowest
survival (Figure 4). Patients with HCT 25% who wereFIGURE 2. A-D, Relationship among anemia and transfusion exposure group
crit; RBC, red blood cell; LOS, length of stay.
1484 The Journal of Thoracic and Cardiovascular Surnot transfused had an overall 6-year survival of 92%.
Survival was 82% in patients with HCT<25% who did
not receive a transfusion, and patients with HCT 25%s and outcomes. eGFR, Estimated glomerular filtration rate; HCT, hemato-
gery c December 2013
TABLE 3. Risk-adjusted effect stratified by intraoperative nadir HCT and intraoperative RBC transfusion
Outcome
Nadir HCT<25 and RBC ¼ 0 Nadir HCT 25 and RBC>0 Nadir HCT<25 and RBC>0
Coefficient ± SE P value Coefficient ± SE P value Coefficient ± SE P value
eGFR 1.8  0.61 .004 1.4  1.00 .15 2.9  0.73 <.001
Troponin 0.033  0.034 .3 0.023  0.054 .7 0.087  0.039 .02
Ventilatory support 0.074  0.033 .02 0.304  0.052 <.001 0.305  0.037 <.001
Postoperative length of stay 0.0029  0.015 .8 0.11  0.025 <.001 0.12  0.017 <.001
Risk of death
Early 0.49  0.36 .17 0.76  0.45 .09 0.98  0.36 .007
Late 0.026  0.21 .9 0.18  0.25 .4 0.057  0.24 .8
HCT, Hematocrit; RBC, red blood cell; eGFR, estimated glomerular filtration rate; SE, standard error.
Loor et al Perioperative Managementwhowere transfused had a 74% 6-year survival. The lowest
survival (67%) was observed in patients exposed to both
anemia (HCT<25%) and RBC transfusion.
Risk-adjusted analysis showed that exposure to both ane-
mia (HCT<25%) and RBC transfusion was a risk factor for
early death (Table 3). However, early and late survival was
similar for the other exposure groups (Table 3 and Table E6).
DISCUSSION
Principal Findings
Our prior work demonstrated increased morbidity risk for
both intraoperative RBC transfusion and anemia; what hasFIGURE 3. A-D, Relative effect size stratified by intraoperative red blo
eGFR, Estimated glomerular filtration rate; LOS, length of stay.
The Journal of Thoracic and Carbeen unclear is which one, or combination, is weighted
most heavily in its contribution to poorer outcomes.
Although optimizing preoperative HCT before surgical
intervention is the ideal, it is not uncommon for patients
to be anemic when they present for surgery. Preoperative
anemia is often coupled with procedural blood loss,
phlebotomy, and hemodilution from intravenous fluids
and CPB priming volume, all of which heighten the risk
for developing or worsening anemia.
Our findings illustrate that it is preferable to allow
patients to have a single negative exposure to avoid a double
negative exposure (HCT <25% and RBC transfusion),od cell (RBC) transfusion and intraoperative nadir hematocrit (HCT).
diovascular Surgery c Volume 146, Number 6 1485
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FIGURE 4. Survival after cardiac surgery stratified by intraoperative
nadir hematocrit (HCT) and intraoperative red blood cell (RBC) transfusion
exposure groups.Vertical bars, confidence limits equivalent to1 SE; solid
lines enclosed within dashed 68% confidence bands, parametric estimates.
Numbers of patients remaining at risk appear below the horizontal axis.
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Malbeit no negative exposure is preferable. Patients exposed
to the combination of intraoperative anemia and transfusion
had the greatest risk for renal, cardiac, and pulmonary
morbidities, as well as increased resource use and earlier
death. The trade-off in morbidity risk with a single exposure
varied depending on the exposure.
Single Exposure: Anemia
At a certainvalue, nadirHCTcontributes to complications
as a result of a critical decrease in oxygen supply; however,
the lower cutoff value is unclear. We found that patients
exposed to intraoperative anemia (HCT<25%) alone had
more renal dysfunction, more myocardial injury, and
longer ventilatory support times, yet mortality was not
higher. Other investigations have demonstrated increased
morbidity, increased mortality, and longer postoperative
LOS in cardiac surgical patients with low nadir HCT.3,16-19
Recently, our group reported more end-organ dysfunction
andmortality associatedwith lower nadirHCTduringCPB.2
Our prior investigation was unable to provide a clear
cutoff value for lower nadir HCT because the effect of lower
HCT and morbidity was closely tied to patient-specific risk
factors and the specific morbidity measured. This investiga-
tion is consistent with our earlier work on anemia exposure
in demonstrating the kidney’s sensitivity to anemia and
increased resource use, reflective of longer ventilation times.
The Society of Thoracic Surgeons guidelines recommend
tolerance of anemia down to a hemoglobin level of 6 g$dL1
onCPB.Although the exact cutoff value is notwidely agreed
on, the general message is that anemia should be tolerated.20
Single Exposure: Transfusion
Intraoperative RBC transfusion without anemia exposure
was associated with longer ventilatory support duration and1486 The Journal of Thoracic and Cardiovascular Surpostoperative LOS, with mortality trending higher than that
for anemia alone. Several investigations in cardiac surgical
patients have linked RBC transfusion with higher morbidity
and mortality.5-7 A recent randomized trial by Hajjar and
colleagues21 found that more RBC units transfused was
an independent risk factor for poor outcomes. Other
studies have implicated RBC transfusion in greater cardiac
and renal dysfunction, delirium, poor quality of life,
impaired respiratory tract function, and more infectious
complications.7,22,23
Least of 3 Evils
This investigation uniquely examined the interplay of
negative exposures in a single at-risk population. Ideally,
patients with preoperative anemia should have their RBC
mass optimized before surgery. Use of perioperative
blood conservation measures, such as antifibrinolytics,
cell salvage, miniaturized bypass circuits, and retrograde
autologous priming, should be implemented whenever
possible.24-27 Methods are available to predict nadir HCT
on CPB, which is often the trigger for RBC transfusion
(Box E1).28
When one is faced with a projection of an intraoperative
nadir HCT at lower thresholds of anemia, these practice
scenarios may be followed: (1) place a unit of RBCs in the
CPBpumpbefore commencing bypass to avoid patient expo-
sure to anemia; (2) commence CPB and tolerate lower levels
of HCT without RBC transfusion; or (3) commence CPB,
tolerate anemia for a period of bypass time, use methods to
ameliorate anemia, such as ultrafiltration, and transfuse
RBCs after a period of exposure to anemia when amelio-
rating methods are unsuccessful. Patients who are predicted
to have a nadir HCT lower than 25% despite these conserva-
tive measures, or who cannot tolerate blood conservation
measures, such as retrograde autologous priming, may
benefit from a unit of RBCs in the CPB circuit before bypass
is commenced, to prevent the HCT from decreasing lower
than 25% and causing 2 negative exposures.
In a recent pilot investigation, Karkouti and colleagues29
suggested treating preoperative anemia with prophylactic
RBC transfusions as a protective measure against post-
operative acute kidney injury. The authors hypothesized
that transfusing patients days before surgery potentially
decreased its negative effects by allowing time for
functional properties of RBCs to recover and by clearing
senescent RBCs. The authors did not address whether these
patients had iron-deficient anemia and could have been
treated with iron therapy rather than a transfusion.
Certainly, in patients who are not candidates for iron or
erythropoietin therapy, early transfusion might be a
consideration. However, others cautioned against using
RBC transfusion as a prophylactic strategy, noting the
availability of myriad perioperative blood conservation
measures that are preferable to RBC transfusion.30gery c December 2013
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This is a prospective cohort investigation, and unmea-
sured variables have the potential to bias study results. In
addition, this is a single-center investigation, which limits
the generalizability of our findings. Treating HCT as a
categorical, rather than a continuous, variable could
influence results, depending on what cutoff is used. We
chose 25% because lower than this number there were still
enough patients who did and did not get transfused to allow
comparative analysis. Below an HCT of 20%, few patients
at our institution escape RBC transfusions.CONCLUSIONS
Ideally, all cardiac surgical patients would have pre-
operative HCT optimized before surgical intervention;
however, the reality is that patients are prone to being
exposed to both anemia and RBC transfusion periopera-
tively. Our findings have practical implications for clinical
practice. Clearly, a double negative exposure to RBCs and
anemia (HCT<25%) carries the highest morbidity risk;
however, single exposures carry increased morbidity risk
as well. Managing preoperative anemia more aggressively
and implementing measures to avoid development of
operative anemia may circumvent negative exposures and
improve patient outcomes.
We thank Tess Parry for editorial assistance.P
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APPENDIX E1. Variables included in multivariable analyses
Patient variables
Demographic: Age (y),* sex,* race,* height (cm), weight (kg), body surface area (m2), body mass index (kg$m-2)*
Symptoms: New York Heart Association functional class (I-IV),* emergency operation*
Ventricular function: Ejection fraction (%),* prior myocardial infarction*
Coronary anatomic features: Left main trunk disease, right coronary artery system disease, left circumflex coronary artery disease, left anterior
descending coronary artery disease (all, any, 50% stenosis,* 70% stenosis)
Cardiac comorbidity: Atrial fibrillation or flutter,* hypertension,* heart failure,* cardiogenic shock,* intra-aortic balloon pump use,*
ventricular arrhythmia,* prior cardiac operation,* complete heart block/pacer*
Noncardiac comorbidity: History of chronic obstructive pulmonary disease,* non–insulin-treated diabetes,* insulin-treated diabetes,*
pharmacologically treated diabetes,* history of peripheral artery disease,* history of smoking,* carotid disease,*
blood urea nitrogen (mg $ dL1),* bilirubin (mg $ dL1),* hematocrit (%),* creatinine (mg $ dL1), creatinine
clearance (mL $ min1), glomerular filtration rate (mL $ min1 $ 1.73 m2),* prior stroke,* total cholesterol
(mg $ dL1)*
Experience: Date of operation*
Procedure variables
Support: Cardiopulmonary bypass time (min),* myocardial ischemia (min)
Procedures: Isolated coronary artery bypass grafting (CABG),* isolated valve,* isolated valveþ CABG,* internal thoracic artery
graft,* other procedures, number of surgical components
*Variables included in the balancing-score model.
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FIGURE E1. CONSORT-style diagram of patient population. The 4
groups analyzed are color coded as in manuscript Figures 1 through 4.
CPB, Cardiopulmonary bypass; HCT, hematocrit; Intra-op, intraoperative;
post-op, postoperative.
BOX E1. Algorithm for calculating patient-machine hematocrit
The need for and amount of additional red blood cells
to achieve a desired hemoglobin concentration early af-
ter commencing cardiopulmonary bypass is determined
by the patient’s blood volume (VpB) and hemoglobin
concentration before bypass (expressed as hematocrit,
HCTp), and the volume of pump-oxygenator prime
(VmB) and its hemoglobin concentration (expressed as
hematocrit, HCTm). Patient blood volume is estimated
as follows:
VpB ¼ 1000f  wt;
where f is the proportion of body weight attributable to
blood volume; f¼ 0.08 for infants and children up to 12
years of age, f ¼ 0.065 for older patients, and wt is
weight in kilograms. (These are average values for the
proportion of body weight that is blood volume. More
complex regression equations are available for more ac-
curate estimates.28)
Patient (VpRBC) and machine (VmRBC) red blood
cell (RBC) volumes are as follows:
VpRBC ¼ VpB $ HCTp
VmRBC ¼ VmB $ HCTm
Then, mixed patient-machine hematocrit (HCTpm) is
as follows:
HCTpm ¼ ðVpRBCþVmRBCÞ=ðVpBþVmBÞ:
If no blood is in the prime:
HCTpm ¼ VpRBC=ðVpBþVmBÞ:
Reprinted with permission from Kouchoukos NT, Blackstone EH, Hanley FL,
Kirklin JK, eds. Kirklin/Barratt-Boyes cardiac surgery. 4th ed. Philadelphia, PA:
Elsevier; 2012.
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TABLE E1. Patient and procedure factors associated with different
exposures to anemia, transfusions, or both
Factor Coefficient ± SE P value
Nadir HCT<25 and RBC ¼ 0 vs nadir
HCT 25 and RBC ¼ 0
Older age 0.019  0.0031 <.001
Female sex 1.7  0.092 <.001
Lower body mass index 0.065  0.0069 <.001
Prior cardiac operation 0.33  0.12 .007
No atrial fibrillation or flutter 0.57  0.15 .002
Lower preoperative hematocrit 0.36  0.011 <.001
Right coronary artery disease
(50% stenosis)
0.39  0.14 .004
Lower bilirubin* 0.091  0.041 .02
Longer cardiopulmonary bypass time 0.0053  0.00013 <.001
More recent date of operation 0.063  0.0017 .03
Nadir HCT 25 and RBC>0 vs nadir
HCT 25 and RBC ¼ 0
Older age 0.025  0.0056 <.001
Female sex 0.55  0.16 .005
Lower body mass index 0.042  0.012 .006
Prior cardiac operation 1.6  0.12 <.001
Lower preoperative hematocrit 0.23  0.017 <.001
Emergency operation 1.7  0.50 .009
Preoperative intra-aortic balloon
pump use
2.4  0.58 <.001
Lower bilirubin* 0.15  0.069 .03
Prior stroke 0.56  0.22 .009
Procedure other than isolated CABG
or valve
0.79  0.15 <.001
Longer cardiopulmonary bypass time 0.015  0.0017 <.001
Earlier date of operation 0.17  0.048 .004
Nadir HCT<25 and RBC>0 vs nadir
HCT 25 and RBC ¼ 0
Older age 0.065  0.0043 <.001
Female sex 2.2  0.12 <.001
Lower body mass index 0.081  0.0088 <.001
Prior cardiac operation 1.4  0.13 <.001
No atrial fibrillation or flutter 1.1  0.15 <.001
Lower preoperative hematocrit 0.53  0.015 <.001
Right coronary artery disease
(50% stenosis)
0.400  0.16 .01
Emergency operation 2.1  0.49 <.009
Lower bilirubin* 0.21  0.047 <.001
Prior stroke 0.43  0.18 .02
Procedure other than isolated CABG
or valve
0.50  0.12 <.001
Internal thoracic artery graft used 0.57  0.15 .002
Longer cardiopulmonary bypass time 0.019  0.0014 <.001
More recent date of operation 0.089  0.035 .01
HCT, Hematocrit; RBC, red blood cell; CABG, coronary artery bypass grafting; SE,
standard error. *(1/Bilirubin), inverse transformation.
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TABLE E2. Patient variables associated with lower 72-hour minimum estimated glomerular filtration rate
Variable Coefficient ± SE P value Reliability,%*
Compared with nadir HCT 25 and RBC ¼ 0 99
Nadir HCT<25 and RBC ¼ 0 1.8  0.61 .004
Nadir HCT 25 and RBC>0 1.4  1.00 .15
Nadir HCT<25 and RBC>0 2.9  0.73 <.001
Older age 0.19  0.015 <.001 100
Lower preoperative eGFR 0.75  0.0078 <.001 100
African American 3.5  0.78 <.001 84
Male sex 1.6  0.55 .005 67
Cardiogenic shock 12  2.5 <.001 92
Diabetes (insulin dependent) 3.06  0.67 <.001 92
Hypertension 1.9  0.36 <.001 95
Heart failure 1.2  0.43 .006 77
Lower preoperative hematocrity 14  2.6 <.001 99
Atrial fibrillation or flutter 1.5  0.59 .01 86
Higher body mass index 0.38  0.031 <.001 100
Longer time undergoing cardiopulmonary bypass 0.044  0.0052 <.001 100
History of COPD 1.3  0.51 .01 63
Lower ejection fractionz 1.5  0.44 .001 96
Peripheral arterial disease 0.92  0.40 .02 45
HCT, Hematocrit; RBC, red blood cell; eGFR, estimated glomerular filtration rate; COPD, chronic obstructive pulmonary disease; SE, standard error. *Percentage of times
variable appeared in 500 bootstrap models. y(40/Preoperative hematocrit), inverse transformation. z(Ejection fraction/50)2, squared transformation.
TABLE E3. Variables associated with higher troponin (24-hour mean)*
Variable Coefficient ± SE P value Reliability,%y
Compared with nadir HCT  25 and RBC ¼ 0 76
Nadir HCT<25 and RBC ¼ 0 0.033  0.034 .3
Nadir HCT  25 and RBC>0 0.023  0.054 .7
Nadir HCT<25 and RBC>0 0.087  0.039 .02
Atrial fibrillation or flutter 0.13  0.053 .01 54
Male sex 0.13  0.028 <.001 56
No prior cardiac operation 0.085  0.033 .01 97
Preoperative intra-aortic balloon pump use 0.70  0.12 <.001 97
Lower preoperative eGFRz 0.35  0.034 <.001 100
Diabetes (non–insulin dependent) 0.075  0.036 .04 91
Lower weightx 0.32  0.048 <.001 100
Longer time undergoing cardiopulmonary bypassk 0.84  0.027 <.001 100
Higher total cholesterol{ 0.012  0.0056 .04 84
Higher blood urea nitrogen 0.0038  0.0014 .009 74
LCx disease (70% stenosis) 0.12  0.027 <.001 97
Nonemergency operation 0.29  0.0104 .005 80
Procedure other than isolated CABG 0.21  0.028 <.001 100
Earlier date of operation 0.073  0.0068 <.001 85
HCT, Hematocrit; RBC, red blood cell; eGFR, estimated glomerular filtration rate; LCx, left circumflex coronary artery; CABG, coronary artery bypass grafting; SE, standard
error. *Log(troponin – 24-hour mean); logarithmic transformation was used as the response variable. yPercentage of times variable appeared in 500 bootstrap models.
zLog(preoperative eGFR), logarithmic transformation. x(80/Weight), inverse transformation. kLog(time on pump þ 1), logarithmic transformation. {(Total cholesterol/120)2,
squared transformation.
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TABLE E4. Variables associated with longer duration of postoperative ventilatory support*
Variable Coefficient ± SE P value Reliability,%y
Compared with nadir HCT  25 and RBC ¼ 0 100
Nadir HCT<25 and RBC ¼ 0 0.074  0.033 .02
Nadir HCT  25 and RBC>0 0.304  0.052 <.001
Nadir HCT<25 and RBC>0 0.305  0.037 <.001
Older age 0.0083  0.00074 <.001 100
Higher NYHA functional class 0.043  0.014 .004 97
History of smoking 0.062  0.017 .004 85
Higher body mass index 0.020  0.0015 <.001 100
History of COPD 0.19  0.027 <.001 100
Prior cardiac operation 0.15  0.033 <.001 94
Longer time undergoing cardiopulmonary bypass 0.0045  0.00029 <.001 100
Preoperative intra-aortic balloon pump use 1.2  0.12 <.001 100
Emergency operation 0.90  0.11 <.001 99
Heart failure 0.062  0.023 .008 84
Prior stroke 0.15  0.034 <.001 96
Prior myocardial infarction 0.12  0.022 <.001 83
Lower ejection fractionz 0.26  0.034 <.001 100
Peripheral arterial disease 0.089  0.022 <.001 68
Higher bilirubinx 0.023  0.0056 <.001 91
Hypertension 0.094  0.019 <.001 83
Procedure other than isolated CABG or valve 0.17  0.021 .001 100
HCT, Hematocrit; RBC, red blood cell;NYHA, New York Heart Association; COPD, chronic obstructive pulmonary disease; CABG, coronary artery bypass grafting; SE, standard
error. *Log(ventilatory support duration); logarithmic transformation was used as the response variable. yPercentage of times variable appeared in 500 bootstrap models.
zLog(ejection fraction), logarithmic transformation. x(Bilirubin)2, squared transformation.
TABLE E5. Patient and procedural variables associated with longer postoperative length of stay*
Variable Coefficient ± SE P value Reliability,%y
Compared with nadir HCT  25 and RBC ¼ 0 100
Nadir HCT<25 and RBC ¼ 0 0.0029  0.015 .8
Nadir HCT  25 and RBC>0 0.11  0.024 <.001
Nadir HCT<25 and RBC>0 0.12  0.017 <.001
Older agez 0.058  0.0053 <.001 100
Atrial fibrillation or flutter 0.061  0.015 <.001 97
Higher NYHA functional class 0.040  0.0056 <.001 100
Heart failure 0.041  0.011 <.001 92
Prior stroke 0.10  0.016 <.001 100
History of COPD 0.10  0.012 <.001 100
Cardiogenic shock 0.40  0.063 <.001 94
Female sex 0.050  0.012 <.001 52
Lower ejection fractionx 0.16  0.016 <.001 100
Higher blood urea nitrogen 0.0027  0.00053 <.001 62
Higher body mass indexk 0.15  0.017 <.001 100
Diabetes (insulin dependent) 0.053  0.017 .001 95
Emergency operation 0.17  0.051 .006 58
Higher bilirubin 0.059  0.0096 <.001 99
Peripheral arterial disease 0.034  0.011 .007 62
Prior cardiac operation 0.042  0.016 .007 53
Procedure other than isolated CABG or valve 0.081  0.097 <.001 100
Endocarditis 0.086  0.020 <.001 97
Longer time undergoing cardiopulmonary bypass 0.041  0.0045 .004 99
Earlier date of operation{ 0.0025  0.00045 <.001 58
HCT, Hematocrit; RBC, red blood cell;NYHA, New York Heart Association; COPD, chronic obstructive pulmonary disease; CABG, coronary artery bypass grafting; SE, standard
error. *Log(postoperative length of stay); logarithmic transformation was used as the response variable. yPercentage of times variable appeared in 500 bootstrap models.
zExp(age/50), exponential transformation. xLog(ejection fraction), logarithmic transformation. k(Body mass index/40)2, squared transformation. {(Years from 1/1/2004 to
date of operation)2, squared transformation.
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TABLE E6. Incremental risk factors for mortality
Factor Coefficient ± SE P value Reliability,%*
Early decreasing phase
Compared with nadir HCT  25 and RBC ¼ 0 92
Nadir HCT<25 and RBC ¼ 0 0.49  0.36 .17
Nadir HCT  25 and RBC>0 0.76  0.45 .09
Nadir HCT<25 and RBC>0 0.98  0.36 .007
Heart failure 0.79  0.18 <.001 84
Prior stroke 0.66  0.21 .002 78
Higher bilirubiny 0.052  0.013 .001 49
Lower preoperative eGFRz 0.605  0.16 .001 66
Lower total cholesterolx 1.1  0.46 .02 77
Procedure other than isolated CABG or valve 0.35  0.18 <.001 68
Propensity of nadir HCT<25 and RBC ¼ 0 0.57  0.73 .4
Propensity of nadir HCT  25 and RBC>0 2.2  1.1 .05
Propensity of nadir HCT<25 and RBC>0 1.4  0.44 .002
Late increasing phase
Compared with nadir HCT  25 and RBC ¼ 0 42
Nadir HCT<25 and RBC ¼ 0 0.026  0.21 .9
Nadir HCT  25 and RBC>0 0.18  0.25 .4
Nadir HCT<25 and RBC>0 0.057  0.24 .8
Older agek 0.66  0.066 <.001 100
Emergency operation 1.00  0.42 .02 50
Complete heart block/pacer 0.41  0.17 .02 51
Lower ejection fraction{ 0.56  0.11 <.001 96
History of COPD 0.67  0.11 <.001 100
History of smoking 0.43  0.11 <.001 98
Peripheral arterial disease 0.53  0.11 <.001 97
Lower preoperative eGFR# 0.22  0.028 <.001 95
Lower preoperative HCT** 1.5  0.51 .003 98
Diabetes (pharmacologically treated) 0.49  0.102 <.001 50
Propensity of nadir HCT<25 and RBC ¼ 0 0.72  0.47 .12
Propensity of nadir HCT  25 and RBC>0 0.503  0.76 .5
Propensity of nadir HCT<25 and RBC>0 0.13  0.41 .8
HCT, Hematocrit; RBC, red blood cell; eGFR, estimated glomerular filtration rate; CABG, coronary artery bypass grafting; COPD, chronic obstructive pulmonary disease; SE,
standard error. *Percentage of times variable appeared in 500 bootstrap models. y(Bilirubin)2, squared transformation. zLog(preoperative eGFR), logarithmic transformation.
x(100/Total cholesterol), inverse transformation. kExp(age/50), exponential transformation. {(Ejection fraction/50)2, squared transformation. #(75/Preoperative eGFR), inverse
transformation. **(40/Preoperative HCT), inverse transformation.
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